New application of composition

Abstract

The invention relates to the technical field of health-care functional food, in particular to novel application of a composition. The composition provided by the invention is prepared from the following raw materials in parts by weight: 120 parts of lotus leaves, 30 parts of haws and 80 parts of mulberry leaves. The raw materials are mainly selected from medicinal and edible food materials and part of common nutritional food materials which are all natural plant raw materials. The applicant deeply studies the characteristics of the raw materials, carries out comprehensive and systematic in-vivo and in-vitro experimental verification respectively by screening and blending various food raw materials according to the two characteristics of preventing and reducing obesity of the product, and finally determines the composition of the optimized variety of the raw materials. The invention also relates to an application of the functional health-care food for preventing and reducing obesity and synchronously protecting intestinal barriers and liver tissues, and the functional health-care food is used for preventing and reducing obesity by inhibiting the whitening of brown fat, promoting the browning of white fat and enhancing the heat energy conversion of body lipid after being taken.

Description

Technical Field

[0001] This invention relates to the field of functional health food technology, and more specifically, to a composition having a novel application in the preparation of functional health foods that prevent and reduce obesity while simultaneously protecting the intestinal barrier and liver tissue. Background Technology

[0002] Obesity is a chronic metabolic disease, often accompanied by complications such as diabetes, coronary heart disease, hypertension, hyperlipidemia, and non-alcoholic fatty liver disease. In the 1980s and 90s, obesity had become a major health problem in developed countries. However, with economic development and changes in dietary habits, obesity has become widespread globally, with its growth rate increasing year by year. In recent years, obesity, as a chronic disease, has posed an increasingly significant threat to people's physical and mental health.

[0003] Obesity is a complex process resulting from the interaction of one or more factors, primarily including genetic inheritance, endocrine abnormalities, overnutrition, unhealthy eating habits, and insufficient physical activity. Under the influence of these factors, fat intake or production exceeds its breakdown rate, gradually leading to fat accumulation in the body, ultimately manifesting as localized or overall obesity.

[0004] Currently, orlistat is the only drug approved in my country for treating obesity. However, long-term use of orlistat may cause certain side effects, including gastrointestinal adverse reactions, leading to oily stools, or deficiencies in fat-soluble vitamins, and even liver damage in some patients. Therefore, long-term use of weight-loss drugs to alleviate obesity is not the best option for obese individuals. Compared to using chemical drugs for weight loss, people tend to prefer adjusting their diet and increasing exercise. However, many weight-loss foods currently available achieve their effects by promoting excretion or increasing satiety to reduce food intake in obese individuals. While these products may alleviate obesity to some extent, from a scientific perspective, a significant reduction in food intake affects the body's absorption of essential nutrients, and long-term use may cause other adverse symptoms in obese individuals. Therefore, there is currently a lack of a safe and effective weight-loss product on the market that can provide weight-loss effects similar to orlistat without adverse side effects, while also meeting the body's nutritional needs.

[0005] In recent years, with the general improvement of people's living standards, the increasing popularity of knowledge about food hygiene and nutrition, and the growing public awareness of health, the concept of scientific and healthy weight loss has been recognized by more and more people. In Western countries, some have proposed replacing pharmacies with kitchens and medicines with food. The traditional Chinese concept of "medicine and food sharing the same origin" reflects the idea of ​​food-based health maintenance, encompassing dietary therapy, health preservation, and medicinal cuisine within traditional Chinese medicine. Therefore, improving health through diet therapy is a widely accepted and advocated approach.

[0006] In the face of the growing number of obese patients, based on the concepts of scientific and healthy weight loss, and from the perspective of "medicine and food sharing the same origin," it is of considerable market value to develop a functional health food that can safely and effectively exert weight loss effects while meeting the differentiated nutritional needs of people of different genders and age groups. Summary of the Invention

[0007] The purpose of this invention is to overcome the technical problems in the prior art and provide a functional health food that can not only prevent and reduce obesity, but is also suitable for both men and women and protect the intestinal barrier.

[0008] This invention provides a functional health food for preventing and reducing obesity, comprising the following ingredients in parts by weight: 100-300 parts lotus leaf, 20-80 parts mulberry leaf, and 30-100 parts hawthorn.

[0009] Preferably, the functional health food contains the following ingredients in parts by weight: 100-300 parts lotus leaf, 20-80 parts mulberry leaf, 20-80 parts tea leaf, and 30-100 parts hawthorn.

[0010] Preferably, the functional health food further comprises the following ingredients in parts by weight: 20-80 parts of cassia seed, 150-400 parts of soybean, 20-100 parts of wolfberry, and 20-100 parts of psyllium husk.

[0011] Preferably, the functional health food also contains the following ingredients in parts by weight: 20-30 parts roselle, 20-30 parts red dates, 20-30 parts black goji berries, 20-30 parts polygonatum, and 20-30 parts lily.

[0012] Preferably, the functional health food also contains the following ingredients in parts by weight: 20-30 parts kudzu root, 20-30 parts bitter orange flower, 20-30 parts maca, 20-30 parts almond, and 20-30 parts sesame.

[0013] Preferably, the functional health food further comprises the following ingredients in parts by weight: 20-30 parts olives, 20-30 parts white kidney beans, 20-30 parts konjac, 20-30 parts coix seed, and 20-30 parts alpinia oxyphylla.

[0014] Preferably, the functional health food further comprises the following ingredients in parts by weight: 20-30 parts bitter melon, 20-30 parts sesame, 20-30 parts Japanese raisin tree seeds, 20-30 parts pumpkin seeds, and 20-30 parts yam.

[0015] This invention also provides a method for preparing a functional health food, comprising the following steps:

[0016] Step 1: Select and clean the above raw materials. Cut some raw materials into pieces or coarsely crush them. Select fruits and vegetables that can be eaten raw and dry them with hot air at a low temperature of 50-60℃ until the moisture content is below 10%. Alternatively, after processing with freeze-drying, they can be ultra-finely pulverized and sieved at -30 to -10℃.

[0017] Step 2: The remaining raw materials can be cooked by low-temperature microwave cooking (80-120℃, 10-30 minutes), low-temperature baking (60-120℃, 10-30 minutes), stir-frying (120-150℃, 10-20 minutes), or extrusion puffing (150℃). After cooling and drying, they can be crushed and sieved.

[0018] Alternatively, the remaining raw materials can be processed by colloidal grinding, enzymatic hydrolysis, fermentation, and spray drying to obtain powdered raw materials.

[0019] Step 3: Mix the above raw materials in the specified proportions and package them to obtain the product of this invention.

[0020] Preferably, the freeze-drying process in step one of the above preparation method is as follows: Select fresh food raw materials, wash, remove impurities, drain, slice or cut into small pieces or granules with a diameter of 5mm-20mm, and place the raw materials into freeze-drying chambers for freeze-drying. The first freezing temperature is -35℃, pre-freezing for 2 hours, the first sublimation is at -15℃, the second freezing temperature is at -35℃, pre-freezing for 3 hours, the second sublimation is at -5℃, kept at this temperature for 2 hours, and then the temperature is raised to 25℃ for drying for 3 hours.

[0021] Preferably, step two of the above preparation method, which involves colloidal grinding, enzymatic hydrolysis, fermentation, and spray drying, mainly includes the following steps: selecting commercially available food raw materials, and cleaning and removing impurities;

[0022] Soak the food ingredients in a 0.3% (mass concentration) sodium bicarbonate solution or water for 4-10 hours. Then, grind the food ingredients in a colloid mill according to the proportion. After grinding, filter to obtain a slurry for later use.

[0023] Add 0.75% of a complex enzyme, consisting of cellulase, α-amylase, and saccharifying enzyme in a mass ratio of 1:1:1, to the aforementioned prepared slurry. Perform enzymatic hydrolysis for 2 hours at 55°C to inactivate the enzyme and set aside for later use.

[0024] The enzymatically hydrolyzed slurry was inoculated for fermentation. The fermentation strains were Lactobacillus plantarum and Lactobacillus acidophilus, with an inoculation amount of 9% and an inoculation ratio of Lactobacillus plantarum and Lactobacillus acidophilus of 1:1. The inoculation and fermentation time was 7 hours and the fermentation temperature was 34℃.

[0025] After fermentation, the slurry is homogenized under high pressure at a pressure of 40 MPa for 2-5 minutes.

[0026] The homogenized slurry was then spray-dried. The spray-drying parameters were as follows: spray pressure 0.2 MPa, feed flow rate 400 ml / h, inlet air temperature 160℃, and hot air flow rate 45 m³ / h. 3 / h.

[0027] Preferably, the raw materials of the food of the present invention are all or part of powdered extracts.

[0028] The raw materials of this invention are mainly derived from food ingredients listed in the "Food and Medicine Homologous" catalogue, as well as some common food ingredients. All raw materials in this invention are natural plant-based, and strict quality control is applied during the selection process, ensuring they are purely natural, free of chemical additives, and preserving the effective components of each food to the greatest extent possible. Through research on the characteristics of each raw material, screening and blending of various food ingredients, and in vivo experimental verification, the raw materials, appropriate component ratios, and processing techniques of this invention were ultimately determined. After thorough experimentation and systematic evaluation and analysis, it is clear that the functional health food of this invention can effectively control body weight before obesity occurs and effectively reduce obesity after it has already occurred. Furthermore, in vivo experiments in mice of different sexes have demonstrated its efficacy in both men and women, with some effects superior to established Western medicines. It also has protective effects on the intestinal barrier and liver tissue, making it suitable for long-term consumption.

[0029] Furthermore, this invention selects the most suitable processing and treatment techniques for the characteristics of different food ingredients, which not only preserves the effective components in the food ingredients to the greatest extent, but also improves the solubility and taste, and is more conducive to the body's nutrient absorption. Attached Figure Description

[0030] Figure 1 Example 2: Changes in body weight of mice in each group after 63 days of free feeding. Compared with the model group, *p<0.05, **p<0.01.

[0031] Figure 2 Example 2: White adipose tissue structure in the groin after 63 days of free feeding.

[0032] Figure 3 Example 2: White adipose tissue structure of the epididymis after 63 days of free feeding.

[0033] Figure 4 Example 2: Brown adipose tissue structure after 63 days of free feeding.

[0034] Figure 5 Example 3: Changes in body weight of mice in each group after 135 days of free feeding. Compared with the model group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0035] Figure 6 Example 3: White adipose tissue structure in the groin after 135 days of free feeding.

[0036] Figure 7 Example 3: Uterine white adipose tissue structure after 135 days of free feeding.

[0037] Figure 8 Example 3: Brown adipose tissue structure after 135 days of free feeding.

[0038] Figure 9 Example 3: Distribution of UCP1 in inguinal white adipose tissue after 135 days of free feeding.

[0039] Figure 10 Example 3: Distribution of UCP1 in uterine white adipose tissue after 135 days of free feeding.

[0040] Figure 11 Example 3: Liver tissue structure after 135 days of free feeding.

[0041] Figure 12 Example 3: Colonic tissue structure after 135 days of free feeding. In the figure, squares represent crypt cells, and ellipses represent goblet cells. Detailed Implementation

[0042] Example 1: Functional Health Food Products

[0043] Preparation Example (1)

[0044] Step 1: Select commercially available mulberry leaves and hawthorn raw materials, sort and air-wash them, coarsely crush them to a diameter of about 5mm, and dry them at a low temperature (60℃) until the moisture content is below 15%.

[0045] Step 2: Cook the above ingredients in a low-temperature microwave (120℃, 10 minutes) according to the following weight proportions: 80 parts mulberry leaves and 60 parts hawthorn.

[0046] Step 3: Crush the above mixed raw materials, pass them through a 100-mesh sieve, and bag them to obtain the product of this invention.

[0047] Preparation Example (2)

[0048] Step 1: Select commercially available lotus leaves and hawthorn raw materials, sort and air-wash them, coarsely crush them to a diameter of about 5mm, and dry them at a low temperature (60℃) until the moisture content is below 15%.

[0049] Step 2: Cook the above ingredients in a low-temperature microwave (120℃, 10 minutes) according to the following weight proportions: 80 parts lotus leaf and 60 parts hawthorn.

[0050] Step 3: Crush the above mixed raw materials, pass them through a 100-mesh sieve, and bag them to obtain the product of this invention.

[0051] Preparation Example (3)

[0052] Step 1: Select commercially available lotus leaves, hawthorn, and mulberry leaves as raw materials. Pick, air-wash, coarsely crush to about 5mm in diameter, and dry at low temperature (40℃) until the moisture content is below 15%.

[0053] Step 2: Cook the above ingredients in a low-temperature microwave (120℃, 10 minutes) according to the following weight proportions: 120 parts lotus leaves, 30 parts hawthorn, and 80 parts mulberry leaves.

[0054] Step 3: Crush the above mixed raw materials, pass them through a 100-mesh sieve, and bag them to obtain the product of this invention.

[0055] Preparation Example (4)

[0056] Step 1: Weigh 1 kg of lotus leaves, crush them to 100 mesh, add 10 L of purified water, heat at 100℃ for 2 h, filter, and concentrate the filtrate to 250 ml using a rotary evaporator.

[0057] Step 2: Weigh 1 kg of lotus leaves, crush them to 100 mesh, add 10 L of 95% ethanol, soak at room temperature for 48 h, filter after soaking, and concentrate the filtrate to dryness using a rotary evaporator.

[0058] Step 3: Mix the above raw materials in a 1:1 ratio to obtain the product of the present invention (based on the concentration ratio of the extract, 1 part by weight of the product in Preparation Example 4 is equivalent to 5 parts by weight of lotus leaf).

[0059] Preparation Example (5)

[0060] Step 1: Select commercially available lotus leaves, hawthorn, mulberry leaves, and tea leaves as raw materials. Pick, air-wash, coarsely crush to about 5mm, and dry at low temperature (60℃) until the moisture content is below 15%.

[0061] Step 2: The above ingredients are cooked in a low-temperature microwave (120℃, 5 minutes) + (100℃, 10 minutes) according to the following weight proportions: 100 parts lotus leaf, 60 parts hawthorn, 80 parts mulberry leaf, and 20 parts tea leaves.

[0062] Step 3: Crush the above mixed raw materials, pass them through a 100-mesh sieve, and bag them to obtain the product of this invention.

[0063] Preparation Example (6)

[0064] Step 1: Select commercially available lotus leaves, hawthorn, mulberry leaves, and tea leaves as raw materials. Pick, air-wash, and dry at low temperature (60℃) until the moisture content is below 15%. Coarsely crush into 10-20 mesh powder.

[0065] Step 2: Weigh and mix the above materials according to the following weight proportions: 120 parts lotus leaves, 40 parts hawthorn, 60 parts mulberry leaves, and 40 parts tea leaves, and then extrude and puff them (puffing temperature 140℃, screw speed 200r / min).

[0066] Step 3: Cool the extruded and expanded raw material, pulverize it into ultrafine powder, pass it through a 150-mesh sieve, and bag it to obtain the product of this invention.

[0067] Preparation Example (7)

[0068] Step 1: Select commercially available raw materials such as lotus leaves, hawthorn, mulberry leaves, tea leaves, cassia seeds, soybeans, goji berries, and psyllium husks. Select, air-wash, coarsely crush to a diameter of about 5mm, and dry at low temperature (60℃) until the moisture content is below 15%. Store for later use.

[0069] Step 2: Weigh and mix the above ingredients according to the following weight proportions: 100 parts lotus leaf, 60 parts hawthorn, 80 parts mulberry leaf, 20 parts tea leaves, 20 parts cassia seed, 400 parts soybean, 20 parts wolfberry, and 100 parts plantain seed husk. Microwave at low temperature (120℃, 10 minutes) + (80℃, 10 minutes). After initial cooling, dry with hot air at 60℃ until the moisture content is below 8%.

[0070] Step 3: Crush the above mixed raw materials, pass them through a 100-mesh sieve, and bag them to obtain the product of this invention.

[0071] Preparation Example (8)

[0072] Step 1: Select commercially available raw materials such as lotus leaves, hawthorn, mulberry leaves, tea leaves, cassia seeds, soybeans, goji berries, and psyllium husks. Select, air-wash, coarsely crush to a diameter of about 5mm, and dry at low temperature (60℃) until the moisture content is below 15%. Store for later use.

[0073] Step 2: Weigh and mix the above raw materials according to the following weight proportions: 100 parts lotus leaves, 80 parts mulberry leaves, 20 parts tea leaves, 100 parts hawthorn, 80 parts cassia seeds, 150 parts soybeans, 100 parts wolfberries, and 20 parts psyllium husks. Microwave cook at low temperature (120℃, 10 minutes) + (80℃, 10 minutes). After initial cooling, dry with hot air at 60℃ until the moisture content is below 8%.

[0074] Step 3: Crush the above-mentioned dried raw materials, pass them through a 100-mesh sieve, and pack them into bags to obtain the product of this invention.

[0075] Preparation Example (9)

[0076] Step 1: Select commercially available raw materials such as lotus leaves, mulberry leaves, tea leaves, hawthorn, cassia seeds, soybeans, goji berries, psyllium husks, roselle, red dates, black goji berries, polygonatum, and lily bulbs. Select, air-dry, and coarsely crush to a diameter of about 5mm.

[0077] Step 2: Weigh and mix the above ingredients according to the following weight proportions: 100 parts lotus leaf, 80 parts mulberry leaf, 20 parts tea leaves, 100 parts hawthorn, 80 parts cassia seed, 150 parts soybean, 100 parts goji berries, 20 parts plantain husk, 20 parts roselle, 30 parts red dates, 20 parts black goji berries, 20 parts polygonatum, and 30 parts lily bulb. Bake in an oven (120℃, 10 minutes). After initial cooling, dry with hot air at 50℃ until the moisture content is below 8%.

[0078] Step 3: Crush the above-mentioned dried raw materials, pass them through a 100-mesh sieve, and pack them into bags to obtain the product of this invention.

[0079] Preparation Example (10)

[0080] Step 1: Select commercially available lotus leaves, hawthorn, mulberry leaves, tea leaves, bitter orange blossoms, maca, and goji berries as raw materials. Wash, remove impurities, and drain. Dry with hot air at 60℃ until the moisture content is below 10%. Cool to room temperature and coarsely grind into 1-5mm particles.

[0081] Step 2: Select commercially available cassia seeds, soybeans, almonds, and sesame seeds. Select, remove impurities, and air-wash them. Roast them in a roasting machine (120℃, 20 minutes / 100kg). After initial cooling, dry them at a low temperature (60℃) until the moisture content is below 10%. Coarsely grind them into 1-5mm particles.

[0082] Step 3: Select commercially available kudzu root and psyllium husk, sort, remove impurities, air-wash, and microwave at low temperature (120℃, 10 minutes) + (80℃, 10 minutes) to coarsely grind into 1-5mm particles.

[0083] Step 4: The above freeze-dried raw materials are separately subjected to low-temperature ultrafine pulverization (-30℃~-10℃), passed through a 150-mesh sieve, and the above raw materials are weighed and mixed according to the following weight parts: 100 parts lotus leaf, 80 parts mulberry leaf, 20 parts tea leaves, 100 parts hawthorn, 80 parts cassia seed, 150 parts soybean, 100 parts wolfberry, 20 parts plantain seed husk, 30 parts kudzu root, 20 parts bitter orange flower, 20 parts maca, 20 parts almond, and 20 parts sesame, and then packaged to obtain the product of this invention.

[0084] Preparation Example (11)

[0085] Step 1: Freeze-dry and pulverize some of the fruit and vegetable raw materials. Select fresh lotus leaves, hawthorn, mulberry leaves, tea leaves, olives, and goji berries. Wash, remove impurities, and drain. Slice or dice into small pieces or granules with a diameter of 5mm-20mm. Place the raw materials separately in a freeze-drying chamber for freeze-drying. The first freezing temperature is -35℃ for 2 hours, followed by the first sublimation at -15℃. The second freezing temperature is -35℃ for 3 hours, followed by the second sublimation at -5℃ for 2 hours. Then, continue to raise the temperature to 25℃ for drying for 3 hours. Pulverize the freeze-dried raw materials separately at low temperature (-30℃~-10℃), pass them through a 150-mesh sieve, and store for later use.

[0086] Step 2: Grind, enzymatically hydrolyze, ferment, and spray-dry some of the seed raw materials. Select commercially available soybeans, white kidney beans, Job's tears, konjac, cassia seeds, psyllium husks, and Alpinia oxyphylla. Wash and remove impurities. Soak soybeans and white kidney beans in a 0.3% sodium bicarbonate solution for 10 hours, then peel them to increase protein solubility and remove bitterness and beany taste. Soak goji berries in water for 4 hours, and soak Job's tears, cassia seeds, psyllium husks, and Alpinia oxyphylla in water for 8 hours. The soaked raw materials are mixed according to the following weight proportions: 400 parts soybeans, 20 parts goji berries, 30 parts white kidney beans, and 20 parts Job's tears. The mixture is then ground in a colloid mill (multiple grinding cycles may be necessary depending on the desired particle size). After grinding, the mixture is filtered through a 60-mesh sieve to obtain a slurry. A compound enzyme, consisting of cellulase, α-amylase, and saccharifying enzyme in a mass ratio of 1:1:1, is added to the aforementioned slurry. The mixture is then enzymatically hydrolyzed at 55°C for 2 hours to inactivate the enzyme. The hydrolyzed slurry is then inoculated with... The fermentation process used *Lactobacillus plantarum* and *Lactobacillus acidophilus* as inoculum strains, with an inoculum size of 9% and an inoculum ratio of 1:1. The fermentation time was 7 hours, and the fermentation temperature was 34℃. After fermentation, the slurry was homogenized under high pressure at 40 MPa for 2-5 minutes. The homogenized slurry was then spray-dried into a powder product and stored for later use. The spray-drying parameters were: spray pressure 0.2 MPa, feed flow rate 400 ml / h, inlet air temperature 160℃, and hot air flow rate 45 m³ / h. 3 / h.

[0087] Step 3: Weigh and mix the above raw materials according to the following weight proportions: 100 parts lotus leaf, 60 parts hawthorn, 80 parts mulberry leaf, 20 parts tea, 20 parts olive, and 650 parts spray-dried mixed powder of soybeans, etc., and pack them into bags to obtain the product of this invention.

[0088] Preparation Example (12)

[0089] Step 1: Select fresh lotus leaves, mulberry leaves, tea leaves, hawthorn, goji berries, bitter melon, and yam. Wash, remove impurities, and drain (peel the bitter melon and yam). Cut the others into small pieces or granules of 5-20mm. Place the raw materials separately into a freeze-drying oven for freeze-drying. The first freezing temperature is -40℃, pre-freezing for 2 hours. The first sublimation is carried out at -15℃. The second freezing temperature is -40℃, pre-freezing for 3 hours. The second sublimation is carried out at -5℃, and the temperature is maintained for 2 hours. The temperature is then raised to 25℃ for drying, and the drying time is 3 hours.

[0090] Step 2: Select commercially available cassia seeds, soybeans, psyllium husks, sesame seeds, Japanese raisin tree seeds, and pumpkin seeds. Select, remove impurities, and air-dry them. Roast them in a roasting machine (150℃, 20 minutes / 100kg). After initial cooling, dry them at a low temperature (60℃) until the moisture content is below 10%.

[0091] Step 3: Weigh and mix the above-mentioned raw materials according to the following weight proportions: 100 parts lotus leaf, 80 parts mulberry leaf, 20 parts tea leaves, 100 parts hawthorn, 80 parts cassia seed, 150 parts soybean, 100 parts wolfberry, 20 parts plantain seed husk, 20 parts bitter melon, 20 parts sesame, 20 parts Japanese raisin tree seed, 30 parts pumpkin seed, and 30 parts yam. Grind them together at low temperature (-30℃~-10℃), pass them through a 150-mesh sieve, and package them to obtain the product of this invention.

[0092] Example 2: Evaluation of the preventive effect in non-obese male mice

[0093] Source of materials:

[0094] Functional health food (Meipukang) TM ): Prepared using the processes described in Preparation Example 1 (i.e., Mepcon A) and Preparation Example 2 (i.e., Mepcon C). (Mepcon) TM (This is the trade name to be used when the product of this invention is launched on the market.)

[0095] Orlistat capsules: National Drug Approval Number H20103180, purchased from JD.com, used as the positive control drug in this experiment.

[0096] Laboratory animals: C57BL / 6 mice, purchased from Shanghai Slack Laboratory Animal Co., Ltd., animal specifications: SPF grade, male, 18-25g.

[0097] Basic feed and 60% fat-based high-fat feed were purchased from Jiangsu Xietong Pharmaceutical Bioengineering Co., Ltd.

[0098] Husbandry conditions and environment: Animals were housed at the Comparative Medicine Center of Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute Co., Ltd. (Parent company: Experimental Animal Center of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., License No.: SYXK(Su)2016-0036). Animals were housed in polycarbonate plastic boxes with dimensions of 375mm × 180mm × 160mm (L × W × H), with no more than 5 animals per cage of any sex. Animals were housed in a barrier-controlled environment animal room, with free access to food and water. Environmental conditions were controlled at room temperature of 20℃–26℃, relative humidity of 40%–70%, and alternating light and dark cycles of 12 hours per day.

[0099] Laboratory animal identification method: Experimental groups are distinguished by tags, which specify the topic code, group, grouping date, animal number, and dosage information. Animal numbers within a group are marked on the ear tag.

[0100] I. Experimental Design

[0101] Establishment of a mouse obesity model and preventive drug administration regimen

[0102] C57BL / 6 mice weighing 18-25g were selected as experimental animals. Mice were grouped according to weight, and drug administration began on the day of grouping. Detailed dosing regimens and routes of administration are shown in Table 1 below. D1-63: The positive control group was administered orlistat by gavage at a dose of 84mg / kg, 5 times a week for 9 consecutive weeks.

[0103] Table 1 Animal grouping and drug administration information

[0104]

[0105] During the experiment, there was no significant difference in feed intake among the groups of animals. After 63 days of feeding, the animals were euthanized, and inguinal white fat, epididymal white fat, brown fat, and colon tissue were collected. The wet weight of the inguinal white fat, epididymal white fat, and brown fat tissue was measured. HE staining was used to evaluate the pathological changes of the inguinal white fat, epididymal white fat, and brown fat.

[0106] II. Experimental Results

[0107] 1. Weight changes of animals in each group during 63 days of free feeding.

[0108] The weight of each group of animals in the above program was measured weekly, and the results are shown in [the table below]. Figure 1 .

[0109] The data show that during the 63 days of free feeding (simultaneous modeling and drug administration), compared with the model group, each drug administration group effectively prevented obesity in mice, with the positive control drug, Mepcon C, showing a more significant reduction in mouse weight.

[0110] 2. After 63 days of free feeding, the organ coefficients of each group of animals were...

[0111] Each group of animals in the above-mentioned scheme consisted of 13 mice, and all mice were euthanized. White adipose tissue from the groin, white adipose tissue from the epididymis, and brown adipose tissue were removed, and their wet weight was measured. The data are shown in Table 2.

[0112] Table 2. Organ coefficients of animals in each group after 63 days of free-feeding.

[0113]

[0114] Compared with the model group, *p<0.05, **p<0.01, ***p<0.001.

[0115] The data show that after 63 days of free feeding, in terms of body weight, compared with the normal group, the model group animals showed an increasing trend in body weight, but the difference was not statistically significant (possibly due to the shorter experimental period; however, the model group showed significant obesity symptoms compared with the normal group in all other indicators). Compared with the model group, the positive, Mepcon A, and C groups all showed significant weight loss, with Mepcon A and C groups showing better results. In terms of white adipose tissue in the groin and epididymis, compared with the normal group, the model group animals showed a significant increase in the weight of white adipose tissue in the groin and epididymis. Compared with the model group, the positive, Mepcon A, and C groups all showed a significant decrease in the weight of white adipose tissue in the groin and epididymis, with Mepcon A and C groups showing better results. In terms of brown adipose tissue, compared with the normal group, the model group animals showed a significant increase in the weight of brown adipose tissue, exhibiting obvious whitening. Compared with the model group, the positive, Mepcon A, and C groups showed a significant decrease in the weight of brown adipose tissue, significantly inhibiting the whitening phenomenon, with Mepcon A and C groups showing better results.

[0116] 3. After 63 days of free feeding, the structures of white fat in the groin, white fat in the epididymis, and brown fat in each group of animals were observed.

[0117] The white inguinal fat, white epididymal fat, and brown fat of mice in each group of the above-mentioned scheme were fixed in 10% neutral buffered formalin. After complete fixation, tissue dehydration, embedding, sectioning, and HE staining were performed. After staining, each tissue was examined under an optical microscope at 200x magnification. The results are shown in [Figure number missing]. Figures 2-4 .

[0118] Microscopic examination revealed that, compared to the normal group, the white adipocytes in the inguinal and epididymal adipose tissue of the model group were significantly larger. Compared to the model group, the enlargement of white adipocytes in the positive control group, the Mepcon A group, and the Mepcon C group was inhibited, with the inhibitory effect of the Mepcon A and C groups being more pronounced than that in the positive control group, resulting in a significant reduction in the size of the white adipocytes. Regarding brown adipose tissue, the brown adipocytes in the normal control group were smaller and brown in color, and could convert energy from food into heat through numerous mitochondria, thus performing thermogenesis. After being fed a high-fat diet, the brown adipocytes in the model group mice became larger, with a distinct white adipose tissue appearing around them. Compared to the model group, the size of brown adipocytes in the positive control group, the Mepcon A group, and the Mepcon C group all decreased, with a certain degree of reduction in the volume of the surrounding white adipose tissue, with the Mepcon A and C groups showing a more significant effect.

[0119] The above results suggest that compared with positive control drugs, Mepcon A and C are more effective in inhibiting the accumulation of excess energy in the body and protecting the heat release function of brown fat, thereby preventing obesity symptoms.

[0120] Example 3: Evaluation of the effect of reducing obesity in obese female mice

[0121] Source of materials:

[0122] Health functional food (Meipukang) TM ): It was prepared using the processes described in Preparation Example 2 (i.e., Mepcon C), Preparation Example 3 (i.e., Mepcon D), and Preparation Example 4 (i.e., Mepcon E).

[0123] Orlistat capsules: National Drug Approval Number H20103180, purchased from JD.com, used as the positive control drug in this experiment.

[0124] Laboratory animals: C57BL / 6 mice, purchased from Shanghai Slack Laboratory Animal Co., Ltd., animal specifications: SPF grade, female, 16-20g.

[0125] Basic feed and 60% fat-based high-fat feed were purchased from Jiangsu Xietong Pharmaceutical Bioengineering Co., Ltd.

[0126] Husbandry conditions and environment: Animals were housed at the Comparative Medicine Center of Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute Co., Ltd. (Parent company: Experimental Animal Center of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., License No.: SYXK(Su)2016-0036). Animals were housed in polycarbonate plastic boxes with dimensions of 375mm × 180mm × 160mm (L × W × H), with no more than 5 animals per cage of any sex. Animals were housed in a barrier-controlled environment animal room, with free access to food and water. Environmental conditions were controlled at room temperature of 20℃–26℃, relative humidity of 40%–70%, and alternating light and dark cycles of 12 hours per day.

[0127] Laboratory animal identification method: Experimental groups are distinguished by tags, which specify the topic code, group, grouping date, animal number, and dosage information. Animal numbers within a group are marked on the ear tag.

[0128] I. Experimental Design

[0129] Establishment of a mouse obesity model and drug administration regimen

[0130] C57BL / 6 mice weighing 18-25g were selected as experimental animals. Modeling phase: Mice were grouped according to weight into a normal group and a model group, with 10 animals in the normal group and 50 animals in the model group. Modeling began on the day of grouping; detailed modeling protocols are shown in Table 3 below. After excluding mice with abnormal weight and those that did not form a model, the weight of mice in the model group and the drug-treated group remained significantly different from that of normal mice for two consecutive weeks, exceeding the normal mouse weight by 10%, thus completing the obese mouse model. Drug treatment phase: Mice were grouped according to weight into a normal group, a model group, a positive control group, a Mepcon C group, a Mepcon D group, and a Mepcon E group. Drug treatment began on the day of grouping; detailed drug treatment protocols are shown in Table 4 below. The positive control group was administered orlistat by gavage at a dose of 84mg / kg, 5 times a week for 8 consecutive weeks. The Mepcon E group was administered Mepcon E extract by gavage at a dose of 58g / kg, 5 times a week for 8 consecutive weeks.

[0131] Table 3 Animal grouping and modeling information

[0132]

[0133] Table 4 Animal grouping and drug administration information

[0134]

[0135] During the experiment, there was no significant difference in food intake among the groups. On day 134, after a 24-hour fast, mouse serum was collected. Following serum collection, the animals were euthanized, and inguinal white fat, uterine white fat, brown fat, colon tissue, and liver were collected. The wet weight of the inguinal white fat, uterine white fat, brown fat tissue, and liver was measured. HE staining was used to evaluate the pathological changes in the inguinal white fat, uterine white fat, brown fat, colon tissue, and liver.

[0136] II. Experimental Results

[0137] Validity

[0138] 1. Weight changes of animals in each group during 135 days of free feeding.

[0139] The weight of each group of animals in the above program was measured weekly, and the results are shown in [the table below]. Figure 5 .

[0140] The data showed that during the 76 days of free feeding, compared with the normal group, the model group animals began to show obesity at day 49 of high-fat diet. By day 74, the model group mice maintained a significant difference in weight from the normal group for two consecutive weeks, and the model group mice weighed 10% more than the normal group, meeting the criteria for successful model establishment, i.e., the obesity model was successfully established. Drug administration began on day 77. During the drug administration period, compared with the model group animals, all drug-treated groups showed a significant reduction in the weight of the obese model mice and improved the obesity symptoms. Among them, the positive control drug, Mepcon D, showed a more significant effect.

[0141] 2. After 135 days of free feeding, the body weight and fat mass of the animals in each group were recorded.

[0142] After collecting serum from each group of animals in the above protocol, all mice were euthanized. White adipose tissue from the groin, white adipose tissue from the uterus, and brown adipose tissue were extracted; data are shown in Table 5.

[0143] Table 5. Fat weight of animals in each group after 135 days of free-range feeding.

[0144]

[0145] Compared with the model group, *p<0.05, **p<0.01, ***p<0.001.

[0146] The data show that after 135 days of free feeding, the body weight of mice in the model group was significantly higher than that of the normal group. Compared with the model group, all treatment groups significantly reduced the body weight of obese mice, with the positive control drug and Mepcon D showing better effects. Regarding inguinal and uterine white adipose tissue, the body weight of inguinal and uterine white adipose tissue in the model group was significantly higher than that in the normal group. Compared with the model group, all treatment groups significantly reduced the body weight of inguinal and uterine white adipose tissue in obese mice, with Mepcon D showing better effects. Regarding brown adipose tissue, the body weight of brown adipose tissue in the model group showed an increasing trend compared with the normal group, but the difference was not statistically significant. Compared with the model group, all treatment groups reduced the body weight of brown adipose tissue to some extent, inhibiting the whitening process of brown adipose tissue. In addition, due to the long feeding period in this experiment, the animals showed signs of aging. In normal animals, brown adipose tissue also showed signs of whitening. Compared with the normal group, each treatment group not only inhibited the whitening of brown adipose tissue caused by high-fat diet, but also further inhibited the whitening of brown adipose tissue caused by aging.

[0147] 3. After 135 days of free feeding, the inguinal white fat, epididymal white fat, and brown adipose tissue structures of the animals in each group were as follows:

[0148] The inguinal white adipose tissue, uterine white adipose tissue, and brown adipose tissue from each group of mice in the above-mentioned protocol were fixed in 10% neutral buffered formalin. After complete fixation, the tissues were dehydrated, embedded, sectioned, and stained with hematoxylin and eosin (HE). After staining, each tissue was examined under an optical microscope at 200x magnification. The results are shown in [Figure number missing]. Figure 6-8 .

[0149] Microscopic examination revealed that, compared to the normal group, the white adipocytes in the inguinal and uterine adipose tissue of the model group were significantly larger. After dewaxing, the cytoplasm of the adipocytes was largely washed away, and excessively enlarged adipocytes tended to have indistinct borders. Compared to the model group, the enlargement of white adipocytes in the positive, Mepcon C, D, and E groups was inhibited, and the white adipocytes were significantly smaller. Regarding brown adipose tissue, the brown adipocytes in the normal group mice were smaller and brown in color. After being fed a high-fat diet, the brown adipocytes in the model group mice became larger, with obvious white adipose tissue appearing around them. Compared to the model group, the size of brown adipocytes in the positive, Mepcon C, D, and E groups was reduced, and the volume of the surrounding white adipose tissue was decreased to some extent.

[0150] 4. After 135 days of free feeding, the UCP1 content in the inguinal white adipose tissue, epididymal white adipose tissue, and brown adipose tissue of each group of animals was measured.

[0151] The inguinal white adipose tissue, uterine white adipose tissue, and brown adipose tissue from each group of mice in the above protocol were fixed in 10% neutral buffered formalin. After complete fixation, the tissues were dehydrated, embedded, sectioned, and stained with IHC. After staining, each tissue was examined under an optical microscope at 200x magnification. The results are shown in [Figure number missing]. Figure 9-10 The microscopic images were quantified using ImageJ software, and the results are shown in Table 6.

[0152] Table 6. Fat weight of animals in each group after 135 days of free-range feeding.

[0153]

[0154] Compared with the model group, *p<0.05, **p<0.01, ***p<0.001.

[0155] UCP1 protein (uncoupling protein 1) is a marker of brown adipocytes, participating in the regulation of thermogenesis and energy metabolism in brown adipocytes to maintain the body's energy balance. That is, the higher the UCP1 content in adipose tissue, the more heat energy is generated and the less energy accumulates in the body. Quantitative results showed that, compared with the normal group, the UCP1 protein content in the white adipose tissue of the groin and uterus of the model group was reduced. Compared with the model group, the UCP1 protein content in the white adipose tissue of each drug-treated group was significantly increased, suggesting that after drug administration, the white adipose tissue in the groin and uterus of obese model mice underwent browning (conversion of white adipose tissue to brown adipose tissue), increasing the content of brown adipose tissue, promoting the generation of heat energy in the body, and inhibiting the accumulation of excess energy.

[0156] In brown adipose tissue, the UCP1 protein content was decreased in the model group compared to the normal group. Compared to the model group, the UCP1 protein content in brown adipose tissue was significantly increased in all treatment groups, suggesting that after administration, the thermogenesis efficiency of brown adipose tissue in obese model mice was enhanced, inhibiting the accumulation of excess energy in the body, thereby reducing obesity.

[0157] Security

[0158] After 135 days of free feeding, the organ coefficients of the animals in each group were...

[0159] Liver samples were collected from mice in each group according to the above protocol, and their wet weight data are shown in Table 7. The livers were fixed in 10% neutral buffered formalin. After complete fixation, tissue dehydration, embedding, sectioning, and HE staining were performed. After staining, each tissue was examined under an optical microscope at 200x magnification. The results are shown in Table 7. Figure 11 The microscopic images were quantified using ImageJ software, and the results are shown in Table 7.

[0160] Table 7. Organ coefficients of animals in each group after 135 days of free-feeding.

[0161]

[0162] Compared with the model group, *p<0.05, **p<0.01, ***p<0.001.

[0163] The data show that, compared with the normal group, the liver weight of the model group animals was significantly higher, suggesting that fatty liver may have occurred in the model group. Compared with the model group, all treatment groups could inhibit the increase in liver weight to some extent. Regarding the liver coefficient, compared with the normal group, the liver coefficient (liver weight / animal body weight) of the model group animals was significantly lower, suggesting that the liver was atrophied or had other degenerative changes (fatty liver is characterized by an increased proportion of fat in liver cells, which can lead to functional degeneration of the liver in severe cases), and the increase in liver weight was mainly due to the increased fat content. Compared with the model group, the liver coefficient of all treatment groups rebounded, suggesting that the positive control drug and Mepcon could improve liver atrophy or other degenerative changes in the model animals to some extent.

[0164] Microscopic examination revealed that, compared to the normal group, the proportion of liver cell nuclei per unit area was reduced in the model group, indicating an increase in liver cell volume per unit area. During the later stages of the high-fat diet, lipid droplets appeared in liver cells due to long-term consumption of high-fat foods, leading to increased cell volume and significant fatty liver. Compared to the model group, the proportion of liver cell nuclei per unit area was increased in all treatment groups, indicating that the administration of the medication could inhibit liver cell enlargement and improve fatty liver symptoms in the model group. Among these, the efficacy of the Mepcon C, D, and E groups was superior to the positive control group.

[0165] Colonic tissue structure of animals in each group after 135 days of free feeding

[0166] Colon tissues from mice in each group were fixed in 10% neutral buffered formalin. After complete fixation, the tissues underwent dehydration, embedding, sectioning, and HE staining. Following staining, each tissue was examined under an optical microscope at 200x magnification. The results are shown below. Figure 12 .

[0167] Colonic crypts increase intestinal surface area and promote intestinal absorption; goblet cells secrete mucin, participating in the formation of the intestinal mucus barrier. Microscopic examination revealed that, compared to the normal group, the model group animals exhibited irregular colonic crypt surfaces, reduced crypt numbers, and crypt atrophy; a decrease in goblet cell numbers and intestinal mucus secretion also indicated significant intestinal barrier damage. The positive control group, as well as the Mepcon C and E groups, also showed irregular crypt surfaces and reduced crypt numbers. In contrast, the Mepcon D group exhibited regular colonic crypt surfaces and a significantly increased number of crypts and goblet cells. Mepcon D demonstrated significantly superior efficacy in protecting the intestinal barrier compared to the other groups.

[0168] III. Results Analysis and Conclusions

[0169] Based on the experimental results of Examples 2 and 3 above, it can be reasonably inferred that the functional health food of the present invention not only has the effect of preventing obesity, but also effectively controls and reduces obesity. Through the dual effect of preventing and reducing obesity, it truly meets the weight loss and lipid-lowering needs of slightly overweight and obese individuals; and it is suitable for both men and women. Specifically:

[0170] In terms of obesity prevention, Mepukang works by reducing the size and weight of white adipose tissue in the uterus and groin, inhibiting the whitening of brown adipose tissue, suppressing the enlargement of brown adipose cells, and reducing the weight of brown adipose tissue, thereby preventing obesity.

[0171] Regarding obesity reduction, Mepcon can inhibit the enlargement of white fat cells, inhibit the whitening of brown adipose tissue, and reduce the weight of both white and brown adipose tissue. Simultaneously, it can increase the content of UCP1 protein in adipose tissue, promoting the conversion of excess energy into heat, regulating the body's energy metabolism balance, and effectively protecting the function of brown adipose tissue in converting excess energy into heat, thus exerting its effect in reducing obesity. Mepcon D is particularly effective. Mepcon E is a high-concentration lotus leaf extract, but its weight-loss and lipid-lowering effects are lower than Mepcon D. Furthermore, Mepcon C is a product combining lotus leaf and hawthorn, but its weight-loss and lipid-lowering effects are lower than Mepcon D (a combination of lotus leaf, hawthorn, and mulberry leaf). Mepcon D also has the effect of protecting the intestinal barrier, indicating a synergistic effect of combining lotus leaf, hawthorn, and mulberry leaf. In terms of safety, Mepcon D, while effectively reducing obesity, can further overcome the adverse effects of the positive-positive drug orlistat, such as intestinal barrier damage and liver problems, avoiding the safety issues associated with drug-based weight loss.

[0172] Regarding the applicable population, male mice, equivalent to males, primarily accumulate excess energy in the epididymal white adipose tissue (visceral adipose tissue), a fact well-documented by the weight of this adipose tissue. Experimental results show that the Mepcon A and C groups effectively inhibited the accumulation of excess energy in visceral adipose tissue. However, this does not mean that excess energy in male mice does not accumulate in other adipose tissues. Excess energy also accumulates in the groin white adipose tissue (subcutaneous adipose tissue). Similarly, in obese women, excess energy primarily accumulates in subcutaneous adipose tissue. Experimental results also show that the Mepcon A and C groups effectively inhibited the accumulation of excess energy in subcutaneous adipose tissue.

[0173] Female mice, equivalent to females, primarily accumulate excess energy in the white adipose tissue (subcutaneous adipose tissue) of the groin. This is well-documented by the weight of this adipose tissue. Experimental results show that the Mepcon C, D, and E groups effectively inhibited the accumulation of excess energy in subcutaneous adipose tissue. However, this does not mean that excess energy in female mice does not accumulate in other adipose tissues. Excess energy also accumulates in the white adipose tissue of the uterus (visceral adipose tissue). In male obesity, excess energy primarily accumulates in visceral adipose tissue. Experimental results also show that Mepcon C, D, and E groups effectively inhibited the accumulation of excess energy in visceral adipose tissue. Therefore, Mepcon is suitable for both men and women in reducing obesity.

[0174] On the other hand, we have also designed a comprehensive and systematic animal experimentation and evaluation system.

[0175] Regarding experimental design.

[0176] According to a report in *Nature Reviews Endocrinology*, a Nature sub-journal, rodent obesity models can be broadly categorized into two types: diet-induced obesity and gene knockout-induced obesity. Since the obesity targeted by Meipukang is due to excess energy stored as fat, we initially determined that the animal modeling method would be diet-induced. Secondly, regarding the selection of model animals, rats and mice are the most widely used preclinical animal models for studying metabolic disorders. In recent decades, the popularity of mouse models has surged, with approximately 60% of all preclinical animal studies currently using mice. The inbred C57BL / 6 mouse strain is widely used to establish diet-induced obesity models due to its tendency to exhibit obesity symptoms. Furthermore, the obesity model of the inbred C57BL / 6 mouse shows good correspondence with that of humans (male mice can effectively simulate the characteristics of obese men with high visceral fat and low subcutaneous fat, while female mice can simulate the characteristics of obese women with low visceral fat and high subcutaneous fat), greatly increasing the scientific rigor of Meipukang's efficacy evaluation.

[0177] Regarding indicator selection.

[0178] Regarding efficacy evaluation indicators: extensive literature review revealed that body weight is the most important indicator in obese mouse models. Furthermore, the weight gain in obese mouse models is primarily due to the accumulation of excess energy as fat. We further investigated the function and distribution of adipose tissue. Adipose tissue in humans and mammals can be divided into white adipose tissue and brown adipose tissue. White adipose tissue serves as the body's energy reservoir, storing excess energy as fat, and is mainly distributed around the epididymis, uterus, and groin. Brown adipose tissue, through its key protein UCP1 (uncoupling protein 1), converts excess energy from food into heat, thus performing a thermogenic function. These two types of adipose tissue can interconvert to some extent. For example, in obesity, in addition to the enlargement of white fat cells and increased tissue weight, brown adipose tissue can also whiten, inhibiting the body's conversion of excess energy into heat. Conversely, in reducing obesity, in addition to the reduction in fat cell size and tissue weight, white adipose tissue can brown, enhancing the body's ability to convert excess energy into heat. Therefore, in terms of efficacy indicators, we mainly focused on animal body weight, adipose tissue cell size, tissue weight, and the expression of the key protein UCP1 in brown adipose tissue.

[0179] Regarding safety indicators, considering that the positive control for efficacy evaluation was orlistat, and its adverse reactions are mainly concentrated in gastrointestinal indigestion and liver damage, we focused on the indicators of the pathological structure of the colon and liver in the safety evaluation of orlistat.

Claims

1. A novel use of a composition, characterized in that: The composition comprises the following raw materials in parts by weight: 120 parts lotus leaf, 30 parts hawthorn, and 80 parts mulberry leaf. The new use refers to its application in the preparation of functional health foods that prevent and reduce obesity while simultaneously protecting the intestinal barrier and liver tissue. The functional health foods prevent and reduce obesity by inhibiting the whitening of brown adipose tissue, promoting the browning of white adipose tissue, and enhancing the body's lipid energy conversion after ingestion.

2. The novel application according to claim 1, characterized in that... The method for preparing the composition includes the following steps: Step 1: Select and clean the above raw materials. Cut some raw materials into pieces or coarsely crush them. Select fruits and vegetables that can be eaten raw and dry them with hot air at a low temperature of 50-60℃ until the moisture content is below 10%. Alternatively, after processing with freeze-drying, they can be ultra-finely pulverized and sieved at -30 to -10℃. Step 2: The remaining raw materials can be cooked by low-temperature microwave cooking (80-120℃, 10-30 minutes), low-temperature baking (60-120℃, 10-30 minutes), stir-frying (120-150℃, 10-20 minutes), or extrusion puffing (150℃). After cooling and drying, they can be crushed and sieved. Alternatively, the remaining raw materials can be obtained as powder by colloidal grinding, enzymatic hydrolysis, fermentation and spray drying. Step 3: Mix the above raw materials in the specified proportions and package them to obtain the product of this invention.

3. The novel application according to claim 2, characterized in that, Step 1, the freeze-drying process, is as follows: Select fresh food raw materials, wash, remove impurities, drain, slice or cut into small pieces or granules with a diameter of 5mm-20mm, and place the raw materials separately into freeze-drying chambers for freeze-drying. The first freezing temperature is -35℃, pre-freezing for 2 hours, the first sublimation is at -15℃, the second freezing temperature is -35℃, pre-freezing for 3 hours, the second sublimation is at -5℃, held at this temperature for 2 hours, and then the temperature is raised to 25℃ for drying for 3 hours.

4. The novel application according to claim 2, characterized in that, Step two, the spray drying process following colloidal grinding, enzymatic hydrolysis, and fermentation, mainly includes the following steps: Select commercially available food ingredients, and clean and remove impurities; Soak the food ingredients in a 0.3% (mass concentration) sodium bicarbonate solution or water for 4-10 hours. Then, grind the food ingredients in a colloid mill according to the proportion. After grinding, filter to obtain a slurry for later use. Add 0.75% of a complex enzyme, consisting of cellulase, α-amylase, and saccharifying enzyme in a mass ratio of 1:1:1, to the aforementioned prepared slurry. Perform enzymatic hydrolysis for 2 hours at 55°C to inactivate the enzyme and set aside for later use. The enzymatically hydrolyzed slurry was inoculated for fermentation. The fermentation strains were Lactobacillus plantarum and Lactobacillus acidophilus, with an inoculation amount of 9% and an inoculation ratio of Lactobacillus plantarum and Lactobacillus acidophilus of 1:

1. The inoculation and fermentation time was 7 hours and the fermentation temperature was 34℃. After fermentation, the slurry is homogenized under high pressure at a pressure of 40 MPa for 2-5 minutes. The homogenized slurry was then spray-dried. The spray-drying parameters were as follows: spray pressure 0.2 MPa, feed flow rate 400 ml / h, inlet air temperature 160℃, and hot air flow rate 45 m³ / h. 3 / h.

Images